Chevy Chase Trust Holdings LLC Sells 5,340 Shares of Danaher Corporation (NYSE:DHR)

Chevy Chase Trust Holdings LLC trimmed its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 1.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 389,198 shares of the conglomerate's stock after selling 5,340 shares during the period. Chevy Chase Trust Holdings LLC owned approximately 0.05% of Danaher worth $79,786,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Fortis Capital Advisors LLC raised its position in shares of Danaher by 1.3% during the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock worth $914,000 after purchasing an additional 50 shares during the period. Fayez Sarofim & Co lifted its stake in shares of Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after buying an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC grew its holdings in shares of Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after buying an additional 50 shares during the last quarter. Perennial Investment Advisors LLC increased its position in shares of Danaher by 2.2% during the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock worth $538,000 after acquiring an additional 51 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC raised its holdings in shares of Danaher by 3.1% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock worth $399,000 after acquiring an additional 52 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Transactions at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president now owns 15,179 shares of the company's stock, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by insiders.

Danaher Price Performance

NYSE:DHR traded up $3.38 during trading hours on Wednesday, hitting $200.85. The stock had a trading volume of 4,379,230 shares, compared to its average volume of 3,480,516. The firm has a market capitalization of $143.74 billion, a price-to-earnings ratio of 39.00, a P/E/G ratio of 2.76 and a beta of 0.77. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70. The company has a 50 day simple moving average of $194.11 and a two-hundred day simple moving average of $209.06. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Danaher had a return on equity of 10.80% and a net margin of 15.81%. Research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.64%. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Wolfe Research dropped their target price on Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a report on Monday, April 7th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, April 23rd. JPMorgan Chase & Co. dropped their price target on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 22nd. Stifel Nicolaus raised shares of Danaher from a "hold" rating to a "buy" rating and set a $260.00 target price on the stock in a research report on Friday, March 14th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, April 23rd. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and an average price target of $248.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.